Product Description
Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.
AI Product Description
*The following content is generated by AI and is for reference only.
Mavacamten, chemically known as (S)-N-(4-((3-chlorophenyl)amino)-2-methylpyrimidin-5-yl)methoxyacetamide, is a groundbreaking small molecule therapy designed specifically for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Its molecular formula is C16H16ClN3O2, and it carries the CAS Registry Number 2089875-99-0. This drug represents a significant paradigm shift in cardiology as the first and only approved myosin inhibitor targeting the root cause of cardiac dysfunction in oHCM patients.
Unlike traditional heart failure medications that primarily manage symptoms by reducing heart rate or fluid retention, Mavacamten acts directly on the sarcomere, the fundamental contractile unit of the heart muscle. In oHCM, excessive force generation by cardiac myosin leads to pathological thickening of the ventricular wall and obstruction of blood flow. Mavacamten works by binding reversibly to the myosin motor protein, stabilizing it in an inactive state. By inhibiting the interaction between myosin and actin filaments, it reduces the hypercontractility of the heart without compromising its ability to relax during diastole. This unique mechanism effectively decreases left ventricular outflow tract obstruction and improves diastolic filling, thereby alleviating debilitating symptoms such as dyspnea, fatigue, and chest pain.
Clinical trials have demonstrated substantial improvements in functional capacity, measured by peak oxygen consumption (VO2), and significant reductions in New York Heart Association (NYHA) functional class scores. The drug is typically administered orally once daily with careful dose titration required to monitor cardiac function, as excessive inhibition can lead to reduced ejection fraction. While generally well-tolerated, common side effects include dizziness, fatigue, and potential drug-drug interactions involving CYP enzymes. Mavacamten has been granted regulatory approval by major health authorities, including the FDA and EMA, marking a historic milestone in precision medicine for genetic heart diseases. It offers hope to millions of patients who previously had limited therapeutic options beyond surgical interventions like septal myectomy or alcohol ablation. As research continues, its role may expand to other forms of cardiomyopathy characterized by hypercontractility, solidifying its status as a cornerstone therapy in modern cardiovascular care.
(All Rights Reserved)
